Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group

D. Meytes, M. Elgat, B. Schochat, Y. Sidi, M. Shaklai, Y. Kilim, Y. Danon, G. Nadel, H. Lee, M. Cerney, P. Swanson, E. Chin, J. D. Rosenblatt

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

To define the extent of human T-cell leukaemia virus (HTLV-I) infection among a group of Jewish immigrants to Israel with an increased frequency of adult T-cell leukaemia, various serological and molecular screening methods, including enzyme-linked immunosorbent assay (ELISA) for anti-HTLV-I, ELISA for antibody to recombinant HTLV-I p40tax protein, and molecular detection of infection by polymerase chain reaction (PCR) amplification of HTLV-I proviral DNA from peripheral blood mononuclear cell DNA, were used. By HTLV-I ELISA the overall rate of infection was 12% (24 of 208) among immigrants from Khurusan, northeastern Iran; no HTLV-I carriers were detected among 111 unselected Jewish immigrants from other parts of Iran. There was unexplained clustering of HTLV-I infection within a cohort of 32 elderly women of similar geographic origin in a home for old people-14 were seropositive by ELISA and 19 of 29 were positive by PCR. The findings in this newly identified high-risk population suggest that in addition to ELISA, other screening techniques may be required to detect all carriers in high-risk populations.

Original languageEnglish (US)
Pages (from-to)1533-1535
Number of pages3
JournalThe Lancet
Volume336
Issue number8730-8731
DOIs
StatePublished - Dec 22 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group'. Together they form a unique fingerprint.

  • Cite this

    Meytes, D., Elgat, M., Schochat, B., Sidi, Y., Shaklai, M., Kilim, Y., Danon, Y., Nadel, G., Lee, H., Cerney, M., Swanson, P., Chin, E., & Rosenblatt, J. D. (1990). Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group. The Lancet, 336(8730-8731), 1533-1535. https://doi.org/10.1016/0140-6736(90)93308-C